Home › Trial NCT06700603
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
- Trial IDNCT06700603
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorRui-hua Xu, MD, PhD
- Enrollment48
- Start date2024-11-20
- ConditionsPancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.